Clinical trial
An Open-Label Extension Study Of Lamotrigine In Subjects With Bipolar Disorder
NCT00360126 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00360126 |
|---|---|
| Title | An Open-Label Extension Study Of Lamotrigine In Subjects With Bipolar Disorder |
| Official title | An Open-Label Extension Study to Assess the Safety of Lamotrigine in Subjects With Bipolar Disorder, Who Are in Remission Following a Manic/Hypomanic Index Episode or a Depressive Index Episode. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Bipolar Disorder |
| Intervention type | Drug |
| Interventions | lamotrigine |
| Enrollment | 11 |
| Start date | Oct 1, 2005 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Aug 3, 2006 |
| Last update posted | Mar 30, 2017 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: